Search

John L Evenden

from Philadelphia, PA
Age ~65
Get Report
Also known as:
John Leslie Evenden, Johnl Evenden
Related to:
Robert ColemanMarja Evenden, 64Emily Evenden
Connected to:
Chelsey L Evenden, 32Cory L Evenden, 32James W Evenden, 91Kathy D Evenden, 73Nadia M Evenepoel, 58Sophie Evenepoel, 58Victoria M Evener, 47Austin J Evenhouse, 32Jill K Evenhouse, 69Wendy S Evenhouse, 53

John Evenden Phones & Addresses

  • Philadelphia, PA
  • 101 Wilton Woods Ln, Media, PA 19063 (484) 620-1045
  • Brockton, MA
  • Wellesley, MA
  • 101 Wilton Woods Ln, Media, PA 19063

Work

Position: Self employed

Education

Degree: Graduate or professional degree

Emails

m***[email protected]

Resumes

Resumes

John Evenden Photo 1

Owner, Wiltonlogic

View page
Location:
Media, PA
Industry:
Research
Work:
Cambridge Cognition Jun 2015 - Feb 2018
Director of Science
Cambridge Cognition Jun 2015 - Feb 2018
Scientific Consultant
Northeast Treatment Centers Dec 2013 - Jun 2015
Clinical Team Leader
University of Delaware 2004 - 2012
Adjunct Professor
Villanova University 2004 - 2012
Adjunct Professor
Education:
Penn State Great Valley 2010 - 2012
Master of Business Administration, Masters, Biotechnology, Management Penn State Great Valley 2005 - 2008
Master of Business Administration, Masters Uppsala University 1995 - 1998
Doctorates, Doctor of Philosophy, Philosophy, Pharmacology University of Cambridge 1977 - 1983
Doctorates, Bachelors, Doctor of Philosophy, Bachelor of Arts, Psychology
Skills:
Neuroscience
Pharmacology
Drug Development
Drug Discovery
Pharmaceutical Industry
In Vivo
Cognition
Neuropharmacology
Biomarkers
Animal Models
Research
In Vitro
Life Sciences
Clinical Development
Psychopharmacology
Research Design
Lifesciences
Neuropsychology
Cognitive Psychology
Pharmaceuticals
Psychological Testing
Visual Basic
Flash
Actionscript
Web Applications
Human Computer Interaction
Photoshop
Science
Scientific Writing
Research and Development
Project Planning
John Evenden Photo 2

Owner, Wiltonlogic

View page
Position:
Owner at WiltonLogic
Location:
Greater Philadelphia Area
Industry:
Computer Software
Work:
WiltonLogic
Owner
AstraZeneca 1989 - 2008
Associate Director, Behavioural Pharmacology
Education:
University of Cambridge 1977 - 1983
PhD, Experimental Psychology

Business Records

Name / Title
Company / Classification
Phones & Addresses
John Evenden
Wiltonlogic, LLC
Prepackaged Software Services · Commercial Physical Research
101 Wilton Wood Ln, Media, PA 19063
(610) 891-7791
John A Evenden
EVENDEN ENTERPRISES OF FLORIDA, INC

Publications

Us Patents

Composition And Methods Employing It For The Treatment Of 5-Ht-Mediated Disorders

View page
US Patent:
61721050, Jan 9, 2001
Filed:
Jul 9, 1999
Appl. No.:
9/351070
Inventors:
John Evenden - Wellesley MA
Seth-Olov Thorberg - Strangnas, SE
Assignee:
Astra Aktiebolag - Sodertalje
International Classification:
A61K 3135
A61K 3140
US Classification:
514456
Abstract:
The invention relates to a composition comprising a first component (a) which is (R)-3-N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxa mide hydrogen (2R,3R)-tartrate monohydrate and a second component (b) which is a 5-HT reuptake inhibitor, excluding citalopram and paroxetine. The invention is further directed to the preparation of the composition, pharmaceutical formulations containing said composition, and a method of treatment of affective disorders such as mood disorders and anxiety disorders with said composition, as well as a kit containing said composition.

Composition And Methods Employing It For The Treatment Of 5-Ht-Mediated Disorders

View page
US Patent:
61842184, Feb 6, 2001
Filed:
Jul 9, 1999
Appl. No.:
9/349590
Inventors:
John Evenden - Wellesley MA
Seth-Olov Thorberg - Strangnas, SE
Assignee:
Astra Aktiebolag - Sodertalje
International Classification:
A61K 3135
A61K 3140
US Classification:
514217
Abstract:
The invention relates to a composition comprising a first component (a) which is (R)-3N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxam ide hydrogen (2R,3R)-tartrate monohydrate and a second component (b) which is 1-[3-(dimethylamino)propyl]-1-(p-fluorophenyl)-5-phthalancarbonitrile, as the racemate or an enantiomer thereof, in the form of the free base, or a pharmaceutically acceptable salt and/or solvate thereof The invention further concerns the preparation of the composition, pharmaceutical formulations containing said composition, and a method of treatment of affective disorders such as mood disorders and anxiety disorders with said composition, as well as a kit containing said composition.

Composition And Methods Employing It For The Treatment Of 5-Ht-Mediated Disorders

View page
US Patent:
61842192, Feb 6, 2001
Filed:
Jul 9, 1999
Appl. No.:
9/351071
Inventors:
John Evenden - Wellesley MA
Seth-Olov Thorberg - Strangnas, SE
Assignee:
Astra Aktiebolag - Sodertalje
International Classification:
A61K 3135
A61K 3140
US Classification:
514217
Abstract:
The invention relates to a composition comprising a first component (a) which is (R)-5-carbamoyl-8-fluoro-3-N,N-dicyclobutylamino-3,4-dihydro-2H-1-benzopyr an in the form of the free base, or a pharmaceutically acceptable salt and/or solvate thereof, and a second component (b) which is (+)-1-[3-(dimethylamino)propyl]-1-(p-fluorophenyl)-5-phthalancarbonitrile in the form of the free base, or a pharmaceutically acceptable salt and/or solvate thereof. The invention is further directed to the preparation of the composition, pharmaceutical formulations containing said composition, and a method of treatment of affective disorders such as mood disorders and anxiety disorders with said composition, as well as a kit containing said composition.

Composition And Methods Employing It For The Treatment Of 5-Ht-Mediated Disorders

View page
US Patent:
61690988, Jan 2, 2001
Filed:
Jul 9, 1999
Appl. No.:
9/351069
Inventors:
John Evenden - Wellesley MA
Seth-Olov Thorberg - Strangnas, SE
Assignee:
Astra Aktiebolag - Sodertalje
International Classification:
A61K 31445
A61K 3135
US Classification:
514321
Abstract:
The invention relates to a composition comprising a first component (a) which is (R)-3-N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxa mide hydrogen (2R,3R)-tartrate monohydrate and a second component (b) which is paroxetine, in the form of its free base, or a pharmaceutically acceptable salt and/or solvate thereof The invention is further directed to the preparation of the composition, pharmaceutical formulations containing said composition, and a method of treatment of affective disorders such as mood disorders and anxiety disorders with said composition, as well as a kit containing said composition.
Control profile
John L Evenden from Philadelphia, PA, age ~65 Get Report